The Shifting Sands of Time: Is Resveratrol Still the Anti-Aging Answer?

For years, resveratrol reigned as the undisputed “it” supplement in the anti-aging realm. This potent polyphenol, famously found in the skin of red grapes and linked to the enigmatic “French Paradox,”[1] captured the public imagination with the promise of a longer, healthier life neatly encapsulated. Its meteoric rise saw it become a fixture on health store shelves and a daily ritual for those seeking to defy the aging process. But in the ever-advancing world of longevity science, does resveratrol still hold its coveted position, or has its star begun to dim? This blog explores the science, the hype, and where resveratrol stands today in the ongoing quest for extended healthspan.

The Spark: Why Resveratrol Ignited an Anti-Aging Revolution

The fervor surrounding resveratrol erupted in the early 2000s, largely propelled by research suggesting it could emulate the effects of caloric restriction—a scientifically validated method for extending lifespan in various organisms.[2] The proposed mechanism behind this remarkable effect centered on a group of proteins known as sirtuins, often hailed as “longevity genes.”[3]

Unpacking the Science: Sirtuins are critical for maintaining cellular health, undertaking vital tasks from DNA repair to inflammation control. Their function is dependent on a coenzyme called nicotinamide adenine dinucleotide (NAD+).[5] Early studies indicated that resveratrol could activate SIRT1, a key sirtuin, thereby bolstering cellular resilience and promoting longevity.[4] [2] [5] This discovery triggered a cascade of research, with numerous studies pointing to a wide array of potential health benefits.[6]

The Research Behind the Buzz: Promises and Realities

A wealth of preclinical research, primarily in laboratory and animal models, has delved into the potential of resveratrol. The proposed advantages appeared extensive:[7] [8]

• Heart Health: Resveratrol is believed to help reduce inflammation, lower LDL (“bad”) cholesterol, and inhibit the formation of blood clots that can lead to heart attacks and strokes.[9]
• Brain Protection: Some animal studies have suggested that resveratrol may shield brain cells from damage and could play a role in lessening age-related cognitive decline.
• Metabolic Well-being: Research has indicated that resveratrol may improve insulin sensitivity, a crucial factor in the prevention of type 2 diabetes.
• Antioxidant and Anti-inflammatory Power: As a polyphenol, resveratrol functions as an antioxidant, combating the cellular damage caused by free radicals. Its anti-inflammatory properties are also significant, as chronic inflammation is a key driver of the aging process.

These promising findings from preclinical studies fueled the widespread belief that resveratrol was a formidable anti-aging tool for humans.

Human Trials: Dosing, Duration, and a Dose of Reality

Human clinical trials investigating resveratrol have employed a broad spectrum of doses, generally ranging from 150 mg to over 1000 mg per day, with some studies using doses as high as 5,000 mg/day. The duration of these trials has also been varied, spanning from a few weeks to a full year. While some studies have demonstrated benefits in specific populations, such as improvements in metabolic markers for individuals with diabetes, the evidence for its longevity effects in healthy humans has been inconsistent.[10]. This has led to a more critical evaluation of its efficacy as a standalone anti-aging supplement.

Weighing the Pros and Cons

Potential Advantages:

• Targeted Support: For individuals with particular health issues like metabolic syndrome or cardiovascular concerns, research suggests resveratrol may offer specific benefits.    
• Antioxidant Defense: Its well-established antioxidant properties contribute to overall cellular health   
• General Safety: For most healthy adults, resveratrol supplements are generally well-tolerated at moderate doses    

Limitations and Side Effects:

• Low Bioavailability: A significant hurdle for resveratrol is its poor absorption in the human body. This means that even with high doses, the amount that actually enters the bloodstream and reaches the cells can be minimal, often less than 1%.[11]
• Inconsistent Longevity Data in Humans: The initial excitement from animal studies has not been consistently mirrored in human trials focused on extending lifespan
• Gastrointestinal Issues: At higher doses, typically above 1 gram per day, some individuals may experience side effects such as nausea and diarrhea.[12]
• Potential Medication Interactions: Resveratrol may interact with various medications and other drugs. It’s crucial to consult a healthcare professional before beginning supplementation.[13]

The Shifting Tides of Anti-Aging: Is Resveratrol Still in Vogue?

While resveratrol remains a recognized supplement, its status as the leading anti-aging compound has diminished. This shift is partly due to the challenges of its low bioavailability and the lack of robust evidence for lifespan extension in humans. The scientific community and health-conscious consumers are increasingly turning their attention to other, potentially more impactful, supplements that target the aging process through different pathways. [14]

The New Vanguard: Supplements Gaining Ground

The field of longevity research is dynamic, and several other compounds are now at the forefront of scientific investigation.

NAD+ Boosters: NMN and NR

The Rationale: As we age, our levels of NAD+ decline significantly, a drop that is linked to a host of age-related diseases. The current thinking is that instead of trying to activate sirtuins with an external molecule like resveratrol, it may be more effective to directly fuel them by increasing NAD+ levels. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursors, meaning the body can convert them into this essential coenzyme.

The Evidence: Animal studies have shown that elevating NAD+ levels with NMN or NR can enhance mitochondrial function, improve energy metabolism, and even reverse certain aspects of aging.Human clinical trials are ongoing, with early results showing promise for improving various health markers.[15]

Senolytics: Quercetin and Fisetin

The Rationale: Senolytics are compounds that selectively eliminate senescent cells, often referred to as “zombie cells.” These are cells that have ceased dividing but resist dying, and they secrete inflammatory substances that can harm surrounding healthy tissues. The accumulation of these cells is a significant contributor to the aging process. Quercetin, found in many fruits and vegetables, and fisetin, present in strawberries, are two of the most researched natural senolytics.[16]  

The Evidence: Animal studies have demonstrated that clearing senescent cells can delay, prevent, or alleviate numerous age-related conditions. Quercetin is often used in combination with the cancer drug dasatinib in clinical trials to enhance its senolytic effects.[17] There is also research suggesting that these compounds may work in synergy with others like resveratrol.[18]

The Final Word: Has Resveratrol’s Era Passed?

Resveratrol played a pivotal role in bringing the science of aging into the mainstream. It introduced the compelling idea that we could target the aging process at a cellular level. However, as our understanding of the biology of aging has matured, the focus has shifted towards more direct and potentially more potent interventions.

While resveratrol may still offer certain health benefits, particularly for cardiovascular and metabolic health, it is no longer viewed as the anti-aging panacea it was once perceived to be. The current frontrunners in the anti-aging supplement arena are NAD+ boosters like NMN and senolytics such as quercetin, which target fundamental aging processes with what appears to be greater efficacy.

The story of resveratrol is a powerful illustration of the dynamic nature of scientific progress. What was once at the cutting edge of longevity research has now paved the way for even more exciting and promising discoveries. As always, staying informed, consulting with healthcare professionals, and approaching the pursuit of longevity with a blend of scientific curiosity and critical thinking remains the wisest course of action.

References:

1. Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French paradox revisited. Front Pharmacol. 2012 Jul 17;3:141. doi: 10.3389/fphar.2012.00141. PMID: 22822401; PMCID: PMC3398412.
2. Chung JH, Manganiello V, Dyck JR. Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol. 2012 Oct;22(10):546-54. doi: 10.1016/j.tcb.2012.07.004. Epub 2012 Aug 10. PMID: 22885100; PMCID: PMC3462230.
3. Gertz M, Nguyen GT, Fischer F, Suenkel B, Schlicker C, Fränzel B, Tomaschewski J, Aladini F, Becker C, Wolters D, Steegborn C. A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One. 2012;7(11):e49761. doi: 10.1371/journal.pone.0049761. Epub 2012 Nov 21. PMID: 23185430; PMCID: PMC3504108.
4. Das DK, Mukherjee S, Ray D. Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev. 2010 Sep;15(5):467-77. doi: 10.1007/s10741-010-9163-9. Corrected and republished in: Heart Fail Rev. 2011 Jul;16(4):425-35. doi: 10.1007/s10741-011-9234-6. PMID: 20238161.
5. Poljšak B, Kovač V, Špalj S, Milisav I. The Central Role of the NAD+ Molecule in the Development of Aging and the Prevention of Chronic Age-Related Diseases: Strategies for NAD+ Modulation. Int J Mol Sci. 2023 Feb 3;24(3):2959. doi: 10.3390/ijms24032959. PMID: 36769283; PMCID: PMC9917998.
6. Jasiński M, Jasińska L, Ogrodowczyk M. Resveratrol in prostate diseases – a short review. Cent European J Urol. 2013;66(2):144-9. doi: 10.5173/ceju.2013.02.art8. Epub 2013 Aug 13. PMID: 24579014; PMCID: PMC3936154.
7. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health–a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011 Aug;55(8):1129-41. doi: 10.1002/mnfr.201100143. Epub 2011 Jun 20. PMID: 21688389.
8. Pezzuto JM. Resveratrol: Twenty Years of Growth, Development and Controversy. Biomol Ther (Seoul). 2019 Jan 1;27(1):1-14. doi: 10.4062/biomolther.2018.176. PMID: 30332889; PMCID: PMC6319551.
9. Tomé-Carneiro J, Gonzálvez M, Larrosa M, Yáñez-Gascón MJ, García-Almagro FJ, Ruiz-Ros JA, Tomás-Barberán FA, García-Conesa MT, Espín JC. Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann N Y Acad Sci. 2013 Jul;1290:37-51. doi: 10.1111/nyas.12150. PMID: 23855464.
10. Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomás-Barberán FA, García-Conesa MT, Espín JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des. 2013;19(34):6064-93. doi: 10.2174/13816128113199990407. PMID: 23448440; PMCID: PMC3782695.
11. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004 Dec;32(12):1377-82. doi: 10.1124/dmd.104.000885. Epub 2004 Aug 27. PMID: 15333514.
12. Shaito A, Posadino AM, Younes N, Hasan H, Halabi S, Alhababi D, Al-Mohannadi A, Abdel-Rahman WM, Eid AH, Nasrallah GK, Pintus G. Potential Adverse Effects of Resveratrol: A Literature Review. Int J Mol Sci. 2020 Mar 18;21(6):2084. doi: 10.3390/ijms21062084. PMID: 32197410; PMCID: PMC7139620.
13. Detampel P, Beck M, Krähenbühl S, Huwyler J. Drug interaction potential of resveratrol. Drug Metab Rev. 2012 Aug;44(3):253-65. doi: 10.3109/03602532.2012.700715. PMID: 22788578.
14. Smoliga, James & Colombo, Elizabeth & Campen, Matthew. (2013). A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations. Aging. 5. 495-506. 10.18632/aging.100579. 
15. Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018 Mar 6;27(3):513-528. doi: 10.1016/j.cmet.2017.11.002. Epub 2017 Dec 14. PMID: 29249689; PMCID: PMC5842119.
16. Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, Ling YY, Melos KI, Pirtskhalava T, Inman CL, McGuckian C, Wade EA, Kato JI, Grassi D, Wentworth M, Burd CE, Arriaga EA, Ladiges WL, Tchkonia T, Kirkland JL, Robbins PD, Niedernhofer LJ. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018 Oct;36:18-28. doi: 10.1016/j.ebiom.2018.09.015. Epub 2018 Sep 29. PMID: 30279143; PMCID: PMC6197652.
17. Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q, Jordan KL, Kellogg TA, Khosla S, Koerber DM, Lagnado AB, Lawson DK, LeBrasseur NK, Lerman LO, McDonald KM, McKenzie TJ, Passos JF, Pignolo RJ, Pirtskhalava T, Saadiq IM, Schaefer KK, Textor SC, Victorelli SG, Volkman TL, Xue A, Wentworth MA, Wissler Gerdes EO, Zhu Y, Tchkonia T, Kirkland JL. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019 Sep;47:446-456. doi: 10.1016/j.ebiom.2019.08.069. Epub 2019 Sep 18. Erratum in: EBioMedicine. 2020 Feb;52:102595. doi: 10.1016/j.ebiom.2019.12.004. PMID: 31542391; PMCID: PMC6796530.
18. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015 Dec;21(12):1424-35. doi: 10.1038/nm.4000. PMID: 26646499; PMCID: PMC4748967.